
- Home
- Companies
- Bertin Technologies
- Products
Bertin Technologies products
Sterilwave 100 - On-site Medical Waste Treatment Solution
Sterilwave 100 is an on-site solution for the treatment of up to 20kg/h of biomedical waste. Sterilwave 100 is the most compact equipment of the Sterilwave range developed and marketed by Bertin Medical Waste for the on-site treatment of biohazardous waste. Compact and safe, Sterilwave 100 transforms bio-hazardous waste into unrecognizable and inert municipal waste thanks to a 100% electric process combing shredding and microwave sterilization in one single vessel with a 100L capacity. Particularly adapted to small medical facilities such as vaccination centers, Sterilwave 100 treats biomedical waste with a bacterial inactivation up to 6log10.Sterilwave 250 - On-site Medical Waste Treatment Solution
Sterilwave 250 is an on-site solution for the treatment of up to 50kg/h of biomedical waste. Sterilwave 250 is a compact equipment developed and marketed by Bertin Medical Waste for the on-site treatment of biohazardous waste. Compact and safe, Sterilwave 250 transforms bio-hazardous waste into unrecognizable and inert municipal waste thanks to a 100% electric process combing shredding and microwave sterilization in one single vessel with a 250L capacity. Particularly adapted to medium-sized medical facilities, Sterilwave 250 treats biomedical waste with a bacterial inactivation up to 8log10.
BEC - Lamp Kit
BEC SARS-CoV-2 RT-LAMP system is designed for the rapid detection of SARS-CoV-2 genome on the field, in less than 30 minutes.
Antibodies - Bertin Bioreagent
Bertin Bioreagent offers primary and secondary antibodies for laboratories. As essential tools, they are particularly versatile when properly validated.
Enzymatic Immunoassay (ELISA) Kit
The AChE® tracer acts on the Ellman’s Reagent to form a yellow compound that strongly absorbs at 414 nm. The intensity of the color, determined by spectrophotometry, is proportional to the amount of tracer bound to the well and is inversely proportional to the amount of free LEAP-2 present in the well during the immunological incubation.